Autonomix Medical (NASDAQ:AMIX – Get Free Report) posted its earnings results on Tuesday. The company reported ($2.51) EPS for the quarter, topping analysts’ consensus estimates of ($2.62) by $0.11, FiscalAI reports.
Autonomix Medical Trading Down 19.7%
AMIX traded down $0.36 on Wednesday, reaching $1.49. The stock had a trading volume of 666,836 shares, compared to its average volume of 1,694,951. Autonomix Medical has a fifty-two week low of $1.46 and a fifty-two week high of $32.55. The firm has a 50-day moving average of $3.26 and a 200-day moving average of $6.52. The company has a market capitalization of $1.44 million, a price-to-earnings ratio of -0.04 and a beta of -0.70.
Analysts Set New Price Targets
AMIX has been the subject of a number of research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Autonomix Medical in a research report on Monday, October 26th. Wall Street Zen upgraded shares of Autonomix Medical from a “strong sell” rating to a “sell” rating in a research report on Saturday, October 3rd. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $42.00.
View Our Latest Research Report on Autonomix Medical
Autonomix Medical Company Profile
Autonomix Medical, Inc. is a medical device company developing catheter-based technologies for the detection and treatment of conditions involving the peripheral nervous system. The company’s platform is designed to identify neural signals in real time, with the goal of helping physicians locate and selectively treat targeted nerves during minimally invasive procedures. Autonomix’s lead development program is focused on pain associated with pancreatic cancer. Its technology is intended to support targeted nerve ablation, potentially offering an alternative approach for managing pain while reducing the need for more extensive procedures.
Read More
- Five stocks we like better than Autonomix Medical
- On Holding’s Sell-Off Overlooks a Key Part of Its Earnings Story
- Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI Demand
- Alphabet Escalates AI Chip Rivalry With NVIDIA
- Amazon’s Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?
Receive News & Ratings for Autonomix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autonomix Medical and related companies with MarketBeat.com's FREE daily email newsletter.
